What are the long‑term adverse effects of isotretinoin?

Long-Term Adverse Effects of Isotretinoin

Long-term use of isotretinoin primarily causes mucocutaneous effects (dry lips, dry skin), musculoskeletal symptoms (arthralgia, back pain), and lipid/liver enzyme abnormalities, all of which generally resolve after discontinuation, with no established increased risk of neuropsychiatric conditions or inflammatory bowel disease based on population studies 1, 2.

Primary Long-Term Concerns

Mucocutaneous Effects

The most persistent long-term effects involve skin and mucous membranes 1, 2:

• Dry lips (cheilitis): Affects 84-100% of patients and may persist in some cases 3, 4
• Xerosis (dry skin): Occurs in 54-95% of patients 4
• Dry eye syndrome: Reported as an infrequent but probable long-term effect 3

These effects are dose-related and typically mild, rarely necessitating treatment discontinuation 4.

Musculoskeletal System

The skeletal effects of multiple isotretinoin courses remain unknown, making this a critical monitoring area 2:

• Bone mineral density changes: In adolescents (13-18 years), 7.9% showed >4% decrease in lumbar spine density and 10.6% showed >5% decrease in total hip density (adjusted for BMI) 2. Follow-up at 11 months showed recovery in some but persistent deficits in 62.5% of hip measurements 2.

• Hyperostosis and premature epiphyseal closure: Spontaneous reports exist, though a clinical study of 217 pediatric patients showed no hyperostosis after 16-20 weeks at ~1 mg/kg/day 2. The FDA label explicitly states "effects of multiple courses on the developing musculoskeletal system are unknown" 2.

• Arthralgia and myalgia: Occur at increased incidence in pediatric patients and may be severe 2. Persistent musculoskeletal symptoms reported in 2% of patients at mean 4.9-year follow-up 3.

Laboratory Abnormalities

Lipid elevations 1:

• Abnormal triglycerides: 7.1-39% of patients
• Abnormal cholesterol: 6.8-27.2% of patients
• Risk factors include male gender, very fair skin, and elevated pretreatment triglycerides 5

Liver enzyme elevations 1:

• Occur in 0.8-10.4% of patients (approximately 15% per FDA label) 2
• Require discontinuation in 0.9-4.7% of cases
• Generally normalize after discontinuation 2

Debunked or Unsubstantiated Long-Term Risks

Neuropsychiatric Effects

Population-based studies do NOT support increased risk of neuropsychiatric conditions 1:

• Overall relative risk: 0.88 (95% CI: 0.77-1.00) for neuropsychiatric adverse effects
• Multiple studies indicate isotretinoin may actually improve quality of life and decrease anxiety/depression symptoms in patients with moderate-to-severe acne 1

Critical caveat: Despite population-level data showing no increased risk, sporadic case reports with positive challenge/rechallenge exist 1, and recent observational data from Syria reported psychological symptoms in 56.3% of users 6. Given high baseline rates of depression/anxiety in adolescents, clinicians must monitor for mood changes, depression, anxiety, and suicidal ideation 1, 6.

Inflammatory Bowel Disease (IBD)

No increased risk established 1:

• Overall relative risk: 1.13 (95% CI: 0.89-1.43)
• The FDA label mentions an association but acknowledges causality is not established 2
• Patients with abdominal pain, rectal bleeding, or severe diarrhea should discontinue immediately 2

Critical Monitoring and Safety Considerations

Laboratory Monitoring Requirements

Required tests 1:

• Liver function tests
• Fasting lipid panel
• Pregnancy test for patients with pregnancy potential

NOT required 1:

• Complete blood count monitoring (though mild normocytic anemia risk is 0.4%, abnormal WBC 7-10.8%) 1

Duration and Dosing Limitations

The FDA explicitly states: "Long-term use of isotretinoin, even in low doses, has not been studied and is not recommended" 2:

• Recommended duration: 15-20 weeks at 0.5-1 mg/kg/day 2
• It is important that isotretinoin be given at recommended doses for no longer than recommended duration 2
• Effect of long-term use on bone loss is unknown 2

Special Population Concerns

Pediatric patients (12-17 years) 2:

• Use should be given careful consideration, especially where metabolic or structural bone disease exists
• Increased incidence of back pain, arthralgia (sometimes severe), and myalgia compared to adults
• Two patients in an extension study showed up to 3.25% decrease in lumbar spine bone mineral density with a second course 2

Clinical Bottom Line

The 2024 AAD guidelines and FDA labeling converge on this: common long-term effects are mucocutaneous and generally reversible; the primary unknown and concerning long-term risk involves skeletal effects from multiple courses, particularly in growing adolescents 1, 2. A large retrospective study of 720 patients with mean 4.9-year follow-up found only 7.2% reported persistent symptoms, all mild, with no correlation to cumulative dose 3. However, because skeletal effects of multiple courses remain unstudied, isotretinoin should not be used long-term or in multiple courses without compelling indication 2.